Aims/hypothesis Clinical trials are in progress to test thiazolidinediones in neurodegenerative diseases such as Alzheimer's disease that involve deficiencies in brain glucose metabolism. While thiazolidinediones enhance glucose uptake in non-cerebral tissues, their impact on brain energy metabolism has not been investigated in vivo. We thus determined whether the thiazolidinedione pioglitazone reverses the decrease in cerebral glucose utilisation (CGU) in a model of brain metabolic deficiency related to Alzheimer's disease. Results are relevant to diabetes because millions of diabetic patients take pioglitazone as an insulin-sensitising drug, and diabetes increases the risk of developing Alzheimer's disease. Materials and methods The regional pattern of CGU was measured with the 2-deoxy [ 14 C] glucose autoradiographic technique in adult awake mice overexpressing transforming growth factor β1 (TGFβ1), and in wild-type littermates. Mice were treated with pioglitazone for 2 months.
Introduction
Thiazolidinediones such as pioglitazone are commonly used to treat type 2 diabetes because they exert a number of effects on glucose and lipid metabolism, resulting in reduced insulin resistance and increased glucose uptake and utilisation in non-cerebral tissues [1, 2] . The finding that thiazolidinediones are potent inhibitors of inflammation [3] [4] [5] has prompted several clinical trials testing the effects of thiazolidinediones in neurological diseases such as Alzheimer's disease and multiple sclerosis, in which inflammation contributes to pathogenesis [6] . The antiinflammatory properties of pioglitazone in the brain have also been shown in murine models of acute [7] and chronic [8] inflammation, when this thiazolidinedione was administered to the animals orally. Both the metabolic and inflammatory actions of thiazolidinediones have been attributed to changes in gene expression mediated by peroxisome proliferator-activated nuclear receptor (PPAR)-γ, of which thiazolidinediones are ligands [3] . However, several recent studies point to the existence of PPAR-independent effects of thiazolidinediones, such as the regulation of mitochondrial respiration [9] [10] [11] [12] . Impaired mitochondrial activity has been related to insulin resistance [13] and correlated with the clinical state in Alzheimer's disease [14] . These data raise the question of whether thiazolidinediones can determine the metabolic rate of the brain.
So far, the evaluation of cerebral glucose utilisation (CGU), a quantitative measure of neuronal activity that principally reflects integrated synaptic function [15] , has not been used to demonstrate whether thiazolidinediones alter brain energy metabolism in vivo. In vitro studies showing that pioglitazone increases glucose uptake and consumption in muscle cells [16] , adipocytes [17] and astrocytes [9] have suggested that the capacity to stimulate glucose metabolism could be a general property of thiazolidinediones that is also applicable to the brain. Considering the strict dependence that the brain has on glucose as a fuel [15] , a stimulatory action of thiazolidinediones on glucose metabolism would provide an additional therapeutic benefit in pathologies such as Alzheimer's disease. A growing body of evidence supports the idea that alterations in brain glucose metabolism and insulin sensitivity or signalling contribute to the pathogenesis of Alzheimer's disease. Regional decreases in the activity of glycolytic enzymes and in glucose utilisation have been detected in sporadic Alzheimer's disease [18, 19] , and the administration of glucose [20] or insulin [21, 22] can facilitate memory in patients. This evidence has led to the notion of metabolic insufficiency or glucoregulatory impairment in Alzheimer's disease [23] [24] [25] and has provided a strong rationale for the therapeutic use of drugs, such as thiazolidinediones, that increase insulin sensitivity and glucose consumption. Preliminary results consistently suggest that restoring adequate levels of insulin and glucose by using a thiazolidinedione facilitates memory in patients with Alzheimer's disease [26] . Since type 2 diabetes increases the risk of Alzheimer's disease and causes cognitive decline [27, 28] , facilitated glucose utilisation in the brain would provide additional therapeutic benefits to patients taking thiazolidinediones regularly to treat diabetes.
We thus sought to determine whether thiazolidinediones affect brain glucose metabolism in vivo. To this end we tested the effect of pioglitazone treatment on regional CGU using the 2-deoxyglucose autoradiographic technique [15] . We compared the cerebral pattern of CGU in normal mice with that of mice overexpressing transforming growth factor β1 (TGFβ1). When produced in excess, TGFβ1 causes robust astrocytosis and microglia activation, vascular deposition of fibrillar material, decreased CGU and impaired cerebral blood flow [29] [30] [31] . This recently corroborated murine model [32] presents a condition of chronic inflammation [8] and oxidative stress [32] associated with metabolic deficiency which makes them suitable for testing in vivo the combined anti-inflammatory and metabolic actions of thiazolidinediones. Our findings reveal unexpected actions of thiazolidinediones on brain glucose metabolism, which raise the question of whether thiazolidinediones are appropriate for the treatment of neurodegenerative diseases in which deficiencies in glucose metabolism occur.
Materials and methods

Animal groups and treatment
The animals used in this study were heterozygous male and female mice genetically modified to produce a constitutively active form of TGFβ1 under the control of the GFAP promoter on a C57BL/6 background [29] , crossed with wild-type C57BL/6 mice (CERJ, Le Genest-St-Isle, France). Control animals were wild-type littermates. Animals were treated with pioglitazone (Takeda Pharmaceuticals, Lincolnshire, IL, USA) provided in the food at 120 μg/g. The treatment started at 2 months of age, soon after weaning, and lasted 2 months. The daily intake of pioglitazone was approximately 18 mg/kg, which yields low micromolar serum levels of pioglitazone. We had previously shown that orally administered pioglitazone modified TGFβ1-induced pathology [8] : it clearly reduced astrogliosis and microglia activation while increasing hydrocephalus. In addition, pioglitazone caused a small (20-30%) but statistically significant reduction in the level of amyloid β42 but not β40 peptide, in both control and TGFβ mice [8] . These data demonstrate that thiazolidinedione does cross the blood-brain barrier at a functionally effective concentration. The physiological variables of the four experimental groups investigated, including body weights before and after the treatment, are given in Table 1 [31] . For methodological reasons, animals were fasted overnight before CGU measurement. Data are expressed as regional CGU with respect to the value found in the white matter (genu of the corpus callosum) of the same animal, and calculated as a ratio of tracer concentration in Bq/g. Absolute CGU values (mean±SEM) for the genu of the corpus callosum (μmol 100 g −1 min Values are mean±SD None of the differences between groups was significant n number of animals per group; MABP mean arterial blood pressure measured in the femoral artery a Values measured just before the CGU procedure (Hipp) and in the ventral thalamus (VB). Treatment with pioglitazone reduced glucose utilisation mostly in cortical areas (S1), the striatum (CPu, here the tail of the caudate nucleus) and the ventral thalamus. The same colour scale and corresponding relative optical density (ROD) (e) were used for the four autoradiograms. Regional changes in CGU are detailed in Fig. 2 
Results
Neither TGFβ1 overexpression nor pioglitazone significantly altered the physiological parameters at the time of measurement ( Table 1 ). The effects of TGFβ1 overexpression and pioglitazone on regional CGU levels are shown in Figs. 1, 2 and 3 . The representative autoradiograms displayed in Fig. 1 provide a first indication that both TGFβ1 and pioglitazone reduced CGU across the brain. CGU values obtained in three distinct functional systems displayed significant decreases in several brain regions of TGFβ1-overexpressing mice (Fig. 2a ), in accordance with previous studies [30, 31] . Figure 2b shows that pioglitazone did not significantly reverse the decreases caused by TGFβ1, nor did it increase CGU in wild-type mice (Fig. 2c) . Rather, the thiazolidinedione reduced CGU in wild-type mice. As the differences in several regions were close to significance, we grouped together the regions within functional systems. The results displayed in Fig. 3 show that both TGFβ1 overexpression and pioglitazone alone significantly reduced the functional activity in the three systems, whereas pioglitazone in TGFβ1 mice did not. Whether the effects of pioglitazone were affected by TGFβ1 overexpression was determined by evaluating the interaction between TGFβ1 and pioglitazone. When whole functional systems were considered, interaction was significant in the sensory and motor systems (Fig. 3) , validating the abatement of pioglitazone responses in TGFβ1 mice. To better characterise the respective effects of TGFβ1 overexpression and pioglitazone, we then analysed the distribution of the changes in CGU that these factors induced in the brain. Figure 4 shows the percentage changes in the group overexpressing TGFβ1 and the pioglitazone-treated group with regard to control animals. What differentiated the distribution of their effects in the brain is that TGFβ1 was more effective in structures of the hippocampal formation (dentate gyrus, −16%; CA1-3, −14%), where pioglitazone displayed only a minor effect. Conversely, pioglitazone reduced CGU more prominently; for example, in the striatum (−18%) and the medial geniculate body (−17%). Furthermore, a region-to-region analysis of the relationship between CGU changes and basal CGU (i.e. the CGU of wild-type mice on the control diet) confirmed a difference in the actions of TGFβ1 and pioglitazone (Fig. 5) . Regional effects of TGFβ1 overexpression appeared unrelated to the basal glucose metabolic rate of the region (Fig. 5a ), whereas decreases in CGU caused by pioglitazone correlated significantly (p<0.0001) with basal CGU (Fig. 5b) . This indicates that the higher the basal metabolic rate the more responsive was the region to the action of pioglitazone.
Discussion
The main finding of this study is that pioglitazone decreased CGU in multiple brain regions, and that an essential feature of this action is its proportionality to the basal CGU. This is the only case in which pioglitazone has been found to reduce glucose metabolism, since all previous reports showed that this and other thiazolidinediones increase glucose uptake in cultured cells [9, 16, 17] and in vivo, as recently shown in the myocardium of diabetic patients [33] . In addition, pioglitazone did not reverse the decreases in CGU associated with overexpression of TGFβ1, despite the fact that this thiazolidinedione CGU (ratio to white matter) System CGU values are compared using three evaluations: (1) efficiently inhibits the inflammatory reaction in this model [8] . Together, these data support a dual but distinctive action of pioglitazone on glucose metabolism and inflammatory processes in the brain. As glucose utilisation reflects neuronal activity in normal, resting physiological conditions [15, 34] , this finding prompts the question of the effects of thiazolidinediones on brain function. This issue is of current interest since (1) several million diabetic patients take pioglitazone, (2) these patients suffer from a greater rate of cognitive decline [27, 28] , and (3) pioglitazone is being tested for the treatment of neurological diseases (for information about clinical trials in progress see [6] ). Below we discuss the possible mechanisms underlying the changes in brain glucose utilisation induced by pioglitazone in vivo, compared with the effects in cultured cells, and the therapeutic implications. An increase in glucose uptake is suggestive of a neural activation [34] . The increases in glucose uptake in cultured astrocytes or in brain slices were not restricted to pioglitazone, as they were mimicked by other thiazolidinediones, although with different potencies of action [9] . A clue to the underlying mechanism is provided by the findings that pioglitazone reduces mitochondrial respiration and that the lactate content increases in parallel [9] . The triple event of increased glucose uptake and lactate release concomitant with decreased respiration has also been described in skeletal muscle [10] . Such a combination suggests a cause-effect relationship in which the increased glucose uptake may represent an adaptive response, producing ATP via a highly glucose-consuming pathway, which generates lactate. This response would compensate for the decreased oxygen-dependent production of ATP resulting from impaired respiration. If so, the increased CGU could be considered an acute reaction that protects against alterations in mitochondrial function. Interestingly, the effect of thiazolidinediones on mitochondrial respiration appeared to be independent of PPAR [9, 11] . A major difference between in vitro and our in vivo studies is that the former provide information about effects occurring as early as 2 h after the addition of pioglitazone, whereas the latter reflect the effects of 2 months of treatment aimed at modelling the chronic actions of the thiazolidinedione. In brain slices the stimulatory effect of pioglitazone on glucose uptake dissipates several days after initial exposure to the thiazolidinedione [9] . This reveals the transient nature of the rapid increase in glucose uptake. Another difference is that the metabolically available glucose, which is in large excess in vitro, may be limited in vivo. Hence, increased glucose utilisation in vivo, if any, may be short-lasting and limited. Conceivably, reduction in glucose utilisation in pioglitazonetreated mice could represent chronic down regulation of aerobic glucose metabolism in the brain resulting from a reduction in mitochondrial respiration, as shown in cultures. This process would be initiated to maintain the balance between aerobic and anaerobic utilisation of glucose so as to avoid excessive glucose consumption. It presumably consists of multiple adaptive changes, which would account for the regionally differentiated sensitivity to pioglitazone, including local re-equilibration of the glucose metabolic pathways and improvement of the insulin signalling pathway [35, 36] . As a result, the highest, potentially 'excessive' metabolic rate in vivo would be preferentially depressed. Why this action of pioglitazone is specific to the brain remains unclear. The differing effects of TGFβ1 overexpression on CGU throughout the brain indicate the involvement of other mechanisms of action. The decrease in CGU induced by TGFβ1 is probably due to glia inflammation and fibrosis-derived damage. Indeed, the hippocampal formation, in which several regions showed large decreases in CGU, also displayed the strongest inflammation [8] . In regions where a significant interaction was found between pioglitazone and TGFβ1, no further hypometabolism occurred with pioglitazone treatment, as if a minimal metabolic rate had already been attained owing to TGFβ1.
Although the rationale for the therapeutic use of thiazolidinediones to compensate for hypometabolism in Alzheimer's disease has received strong support [20] [21] [22] , the data presented here suggest that long-term administration of pioglitazone may not enhance the capacity of the brain to metabolise glucose in Alzheimer's disease. However, this may not necessarily mean that pioglitazone is deleterious to the brain. First, the possibility cannot be ruled out that the brain utilises more of a fuel other than glucose, such as lactate of peripheral origin [37] . Second, pioglitazone treatment may be protective by limiting the highest rates of regional glucose oxidative metabolism and the concomitant oxidative stress [14, 32, 38, 39] , in association with the benefits derived from the attenuation of inflammation [5] . Finally, pioglitazone can induce the expression of proteins related to the stress response [40] and mitochondrial membrane hyperpolarisation that can safeguard the cells against an excessive metabolic rate [9] . This scenario would be akin to a 'preconditioning' effect in which a drug is beneficial by mildly impairing mitochondrial respiration. In support of these ideas, pioglitazone has been shown to be protective in situations of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration in the mouse model of Parkinson's disease [7] and in acute metabolic stress caused by ischaemia [41] . Extrapolating these findings to diabetic patients should nevertheless be done with caution. Indeed, no cognitive impairment has been reported in patients treated with pioglitazone, and first results from a clinical trial testing the thiazolidinedione rosiglitazone in Alzheimer's disease point to preserved cognition [26] . A very recent study in mice modelling Alzheimer's disease suggests that rosiglitazone attenuates learning and memory deficits by lowering glucocorticoid actions [42] . However, unlike pioglitazone, rosiglitazone does not cross the blood-brain barrier. Therefore, any effect on cognition by rosiglitazone ought to be initiated outside the brain, while pioglitazone would act both centrally and peripherally. Hence, it is premature to conclude that pioglitazone would mimic the beneficial effects of rosiglitazone. Forthcoming studies should address more adequately the repercussions on brain function of the use of different thiazolidinediones, and define the mechanisms by which thiazolidinediones could provide therapeutic benefits in neurological disorders.
